| Title： | Expert consensus on growth and development management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | Endocrinologists and Paediatricians |
| Evidence classification method： | According to the evidence ranking schemes from Oxford Centre for Evidence-Based Medicine (OCEBM) , the evidence from the included studies will be divided into 6 levels of evidence (1a, 1b, 2a, 2b, 3, 4), and the strength of the recommendation will be divided into 3 levels according to the level of evidence: A (strong), B (moderate), and C (weak). |
| Development unit： | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
| Registration time: | 2024-03-25 |
| Registration number： | PREPARE-2024CN460 |
| Purpose of the guideline: | To standardize the treatment and monitoring of growth and development in patients with 21-hydroxylase deficiency, and help specialists to accurately assess, standardize diagnosis and treatment, and avoid misunderstandings in the growth and development management of children with 21-hydroxylase deficiency. |
